BSE Pharma Sector Regulatory Filings — August 11, 2026

11-08-2026

Zydus Lifesciences reported standalone revenue from operations of ₹28,722 million for Q1 FY26, an 11% increase YoY from ₹25,883 million in Q1 FY25, driven by 9.1% growth in product sales. However, net profit declined 11.7% YoY to ₹3,396 million from ₹3,847 million, impacted by higher expenses and a tax rate normalisation after the prior year's benefit. The company completed a ₹11,063 million buyback, extinguishing 0.87% of equity shares, and is monitoring the new labour codes.

• · Other income for Q1 FY26 included a dividend from subsidiaries/joint ventures? No, that dividend (INR 1,033 million) was in the March 31, 2026 quarter; Q1 FY26 had only INR 1,237 million other income (much lower).
• · Exceptional items: nil in Q1 FY26 vs INR 1,068 million impairment in Zydus VTEC in Q4 FY26.
• · Tax expense for Q1 FY26: INR 1,161 million; effective tax rate 25.5% vs Q1 FY25 19.0% (benefit from section 115BAA adoption).
• · Trading window closed till August 13, 2026.
• · Auditors issued unmodified limited review reports.
• · Company has only one segment: Pharmaceuticals.

11-08-2026

Zydus Lifesciences reported Q1 FY27 total revenues of ₹80,170 mn, up 22% YoY, driven by strong India branded formulations (+20% YoY) and International Markets (+34% YoY). However, EBITDA margin contracted sharply by 770 bps to 24.1% from 31.8% a year ago, and reported PAT grew 35.9% YoY to ₹9,398 mn. Net debt stood at ₹59,041 mn as of June 30, 2026.

• · India formulations outperformed IPM in Cardiology, Diabetology, Gynaecology, Anti-infectives, Pain Management, Oncology and Nephrology.
• · Chronic and sub-chronic portfolio share increased to 54.2%, up 360 bps over 4 years.
• · North America formulations declined 2.6% YoY but grew 4.9% QoQ.
• · Consumer Wellness domestic business grew only 5% YoY; seasonal brands de-grew due to softer summer.
• · Net debt to EBITDA ratio improved to 0.34x from 0.70x a year ago.
• · USFDA granted priority review for Saroglitazar Magnesium NDA for PBC.
• · Injectable facility at Zydus Biotech Park received EIR with VAI classification.
• · Net working capital increased to ₹86,143 mn from ₹56,971 mn in Q1 FY26.
• · ESG: Net carbon neutral target by 2035; net water neutral by 2028; 37% renewable energy in total energy mix.

11-08-2026

Torrent Pharmaceuticals Limited has informed the stock exchanges that its representatives will participate in the Emkay - Confluence 2026 investor meet in Mumbai on August 14, 2026, with group and one-on-one sessions. The filing is a routine disclosure under Regulation 30 of SEBI LODR and contains no financial results, business updates, or material information.

11-08-2026

Zydus Lifesciences reported a violation of its Code of Conduct under SEBI PIT Regulations by designated person Mr. Ashutosh Patil (Associate Research Scientist), who inadvertently executed a contra trade (purchase on March 11, 2026, and sale on May 22, 2026) of 171 equity shares worth ₹3,36,166. The company issued a warning letter and Mr. Patil transferred the profit of ₹18,797 to IEPF. No previous violations were noted, and the Audit Committee took note of the matter on August 11, 2026.

• · The contra trade involved purchase on March 11, 2026, and sale on May 22, 2026.
• · Mr. Patil provided an apology letter stating the trade was unintentional and due to oversight.
• · The profit of ₹18,797 was transferred online to IEPF on August 10, 2026 (UTR: 260810281845192).
• · No previous instances of violation were observed since the last financial year.

11-08-2026

Zydus Lifesciences has disclosed that an audio recording of its investor call discussing unaudited financial results for the quarter ended June 30, 2026, is now available on its website. This is a routine regulatory disclosure under SEBI Listing Regulations and does not contain any financial figures or performance details.

• · The audio recording link is https://zyduslife.com/public/pdf/Audio-Recording-of-Investor-Call-11-Aug-2026.mp3
• · The filing is made under regulations 30 and 46(2)(oa) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

11-08-2026

Biocon Limited has informed the stock exchanges that its management will participate in the Motilal Oswal 22nd Annual Global Investor Conference on August 17, 2026, in Mumbai. The company clarified that no unpublished price-sensitive information will be disclosed during the meetings.

11-08-2026

Zydus Lifesciences held its 31st AGM on August 11, 2026, where all 9 resolutions were passed with overwhelming majority. The company declared a final dividend of ₹1 per share for FY2026. Shareholder queries covered capacity expansion, lower standalone results, US pricing pressures, debt reduction, and biosimilar strategy, indicating mixed performance concerns.

• · All resolutions passed with over 90% approval; Item 8 (appointment of Kulin Lalbhai) had the lowest support at 90.44%.
• · Shareholder questions highlighted concerns about lower standalone results, US pricing pressure, and debt reduction plans.
• · The company acknowledged plans for capacity expansion and global biosimilar strategy.
• · The AGM was held via video conferencing, with 106 members attending in person.
• · The final dividend of ₹1 per share was approved, representing a 100% payout on face value of ₹1.

11-08-2026

Zydus Lifesciences Limited announced at its 31st Annual General Meeting on August 11, 2026, the re-appointment of Dr. Sharvil P. Patel as Managing Director for a further five-year term (April 1, 2027 to March 31, 2032) and the appointment of Mr. Kulin S. Lalbhai as an Independent Director for a five-year term (May 19, 2026 to May 18, 2031). These changes ensure leadership continuity and board refreshment, with no financial figures or performance metrics disclosed.

• · Re-appointment of Dr. Sharvil P. Patel as Managing Director effective April 1, 2027 to March 31, 2032.
• · Appointment of Mr. Kulin S. Lalbhai as Independent Director effective May 19, 2026 to May 18, 2031.
• · Shareholders passed ordinary and special resolutions at the 31st Annual General Meeting on August 11, 2026.

11-08-2026

Zydus Lifesciences Limited held its 31st Annual General Meeting on August 11, 2026, where all 9 resolutions were passed with requisite majority. Resolutions included adoption of audited standalone and consolidated financial statements, declaration of a dividend of ₹1 per equity share, re-appointment of directors Pankaj R. Patel and Mukesh M. Patel, and ratification of cost auditors. While most resolutions received near-unanimous support (over 99.9% in favor), the re-appointment of Mr. Mukesh M. Patel saw notable opposition with 1.28% of votes against, and the re-appointment of Mr. Pankaj R. Patel had 0.37% against, indicating some shareholder dissent.

• · The remote e-voting period was from August 8, 2026 (9:00 a.m. IST) to August 10, 2026 (5:00 p.m. IST).
• · The cut-off date for entitlement to vote was August 4, 2026.
• · Resolution 8 (special business) had the highest opposition at 9.56% of votes against.
• · Resolution 7 (special business) had 4.33% of votes against.
• · No invalid votes were recorded for any resolution.
• · The AGM was conducted through Video Conferencing/Other Audio Visual Means as per MCA circulars.

11-08-2026

Zydus Lifesciences held its 31st Annual General Meeting on August 11, 2026, via video conferencing, with 106 shareholders attending. All nine resolutions were passed with overwhelming shareholder support, including the adoption of standalone and consolidated financial statements, declaration of a final dividend of Re. 1 per share, and re-appointments of directors. However, resolutions concerning the re-appointment of Managing Director Dr. Sharvil P. Patel and the appointment of Independent Director Mr. Kulin Lalbhai saw significant opposition from public institutional shareholders, with 23.77% and 52.46% voting against, respectively.

• · The meeting was held through Video Conferencing / Other Audio Visual Means.
• · Total outstanding shares of the company: 997,503,832.
• · Promoter and Promoter Group held 748,273,673 shares (75.0% of total).
• · Public – Institutions held 181,024,401 shares (18.1% of total).
• · Public – Non-Institutions held 68,205,758 shares (6.8% of total).
• · Resolution 8 (Appointment of Mr. Kulin Lalbhai as Independent Director) required Special resolution and received only 90.44% overall votes in favour, with public institutions voting 52.46% against.
• · Resolution 7 (Re-appointment of Dr. Sharvil P. Patel as Managing Director) received 95.67% overall votes in favour, but 23.77% of public institutional votes were against.
• · All other resolutions passed with over 98% votes in favour.

11-08-2026

Zydus Lifesciences reported consolidated revenue from operations of ₹80,170 Million for Q1 FY27, up 22.0% YoY from ₹65,737 Million in Q1 FY26, driven by strong growth in the Consumer Products segment (+67.5% YoY) and the inclusion of recent acquisitions (Amplitude Surgical, Comfort Click, Assertio Holdings). However, consolidated net profit declined 35.9% YoY to ₹9,398 Million from ₹14,668 Million, impacted by exceptional charges of ₹182 Million including severance costs and antitrust settlement provisions, as well as higher depreciation and finance costs. The standalone business saw revenue growth of 11.0% YoY but PAT fell 11.7% YoY. The company completed a ₹11,063 Million buyback extinguishing 0.87% of equity shares.

• · Exceptional items in Q1 FY27 consolidated: ₹1,091 Million provision for severance at Assertio, ₹559 Million provision for antitrust settlement, offset by ₹1,468 Million receipt from Teva settlement.
• · Consumer products segment revenue grew 67.5% YoY to ₹14,359 Million, driven by the Comfort Click acquisition.
• · Medical technologies segment revenue declined 13.6% YoY to ₹2,830 Million, with segment loss of ₹817 Million.
• · Consolidated finance costs increased 84.2% YoY to ₹1,560 Million from ₹847 Million.
• · Consolidated depreciation and amortisation more than doubled to ₹5,547 Million from ₹2,381 Million YoY, reflecting recent acquisitions.
• · Standalone other income fell to ₹1,237 Million from ₹1,571 Million YoY, as prior period included higher dividends from subsidiaries.
• · The company acquired Assertio Holdings for ~USD 166.4 Million (₹23.50 per share) via cash tender offer completed June 16, 2026.
• · Zydus Pharmaceuticals (USA) reached in-principle settlement of class action antitrust lawsuits; no admission of liability.
• · The buyback of 8,730,158 shares (0.87% of equity) was completed on June 18, 2026 at an aggregate cost of ₹11,063 Million.
• · 53 subsidiaries were reviewed by other auditors; 42 subsidiaries' financials were not reviewed by any auditor.